EU Crunch Time For Bluebird’s Neurodegenerative Disorder Gene Therapy
US Filing Expected Mid-2021
The EU could become the first market in which eli-cel is approved if the gene therapy for cerebral adrenoleukodystrophy this week passes muster with the European Medicines Agency.
You may also be interested in...
Myovant, Bayer and Rhythm Pharmaceuticals are among the companies that could soon learn whether the European Medicines Agency thinks their drugs are fit for approval.
A number of advanced therapies are likely to be approved in the EU this year.
The news comes less than a week after data partially exonerated its other gene therapy in a cancer scare announced in February.